Fernandes B, Crankshaw D
Honours Programme in Biology/Pharmacology, McMaster University, Hamilton, Ontario, Canada.
Eur J Pharmacol. 1995 Sep 5;283(1-3):73-81. doi: 10.1016/0014-2999(95)00288-v.
Spontaneous contractile activity of strips of human myometrium obtained from non-pregnant donors at the time of hysterectomy was inhibited by the selective prostanoid DP receptor agonists BW 245C (5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin) and ZK110841 ((5Z,13E)-(9R,11R,15S)-9 beta-chlor-15-cyclohexyl-11,15-dihydroxy-16,17,18,19, 20-pentanor-5,13-prostadienoic acid) with pEC50 values of 8.4 and 7.3 respectively but prostaglandin D2 produced a biphasic effect. In the presence of the TP receptor antagonist L670596 ((-)-6,8-difluoro-9-p-methylsulfonyl benzyl-1,2,3,4-tetrahydrocarbazol-1-yl-acetic acid), contractile activity induced by the FP receptor agonist, cloprostenol ([1R-[1 alpha(Z),2 beta(1E,3R),3 alpha,5 alpha]]-7-[2-[4-(3- chlorophenoxy)-3-hydroxy-7-butenyl]-3,5-dihydroxycyclopentyl]-5-he ptenoic acid), was inhibited by BW 245C (pEC50 = 7.5), ZK110841 (pEC50 = 6.7) and prostaglandin D2 (pEC50 = 6.3). Under these conditions both prostaglandin J2 and 9 alpha,11 beta-prostaglandin F2 were inhibitory partial agonists. All compounds were antagonized by the selective DP receptor antagonist BW A868C (3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)h ydantoin), but the pKB values were both concentration-dependent (pKB versus BW 245C at 10 nM = 9.1, at 50 nM = 8.3) and agonist-dependent (pKB at 10 nM versus BW 245C = 9.1, versus ZK110841 = 7.4). Both agonist and antagonist potencies support the existence of DP receptors in human myometrium. The concentration and agonist dependence of the action of BW A868C suggests that putative DP receptor agonists relax human myometrium by more than one mechanism. These observations may be explained by the existence of subtypes of DP receptor in human myometrium.
在子宫切除时从非妊娠供体获取的人子宫肌层条带的自发收缩活动,受到选择性前列腺素DP受体激动剂BW 245C(5-(6-羧基己基)-1-(3-环己基-3-羟丙基)乙内酰脲)和ZK110841((5Z,13E)-(9R,11R,15S)-9β-氯-15-环己基-11,15-二羟基-16,17,18,19,20-五降-5,13-前列腺二烯酸)的抑制,其pEC50值分别为8.4和7.3,但前列腺素D2产生双相效应。在TP受体拮抗剂L670596((-)-6,8-二氟-9-对甲基磺酰基苄基-1,2,3,4-四氢咔唑-1-基-乙酸)存在的情况下,FP受体激动剂氯前列醇([1R-[1α(Z),2β(1E,3R),3α,5α]]-7-[2-[4-(3-氯苯氧基)-3-羟基-7-丁烯基]-3,5-二羟基环戊基]-5-庚烯酸)诱导的收缩活动受到BW 245C(pEC50 = 7.5)、ZK110841(pEC50 = 6.7)和前列腺素D2(pEC50 = 6.3)的抑制。在这些条件下,前列腺素J2和9α,11β-前列腺素F2均为抑制性部分激动剂。所有化合物均被选择性DP受体拮抗剂BW A868C(3-苄基-5-(6-羧基己基)-1-(2-环己基-2-羟乙氨基)乙内酰脲)拮抗,但pKB值既依赖于浓度(10 nM时与BW 245C相比pKB = 9.1,50 nM时为8.3)又依赖于激动剂(10 nM时与BW 245C相比pKB = 9.1,与ZK110841相比为7.4)。激动剂和拮抗剂的效力均支持人子宫肌层中存在DP受体。BW A868C作用的浓度和激动剂依赖性表明,假定的DP受体激动剂通过不止一种机制使人子宫肌层松弛。这些观察结果可能由人子宫肌层中DP受体亚型的存在来解释。